Stocktoria
MAIA Biotechnology, Inc. MAIA
NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2022-07-28
MAIA Biotechnology, Inc. financials (annual, from 10-K)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | — |
| R&D expense | $453,745 | $10.0M | $11.1M | $8.9M | $3.5M |
| Operating income | -$24.3M | -$17.0M | -$20.2M | -$16.2M | -$7.8M |
| Interest expense | — | $57 | $6,863 | $6,967 | $827,539 |
| Income tax | $2,000 | $2,000 | — | — | — |
| Net income | -$22.4M | -$23.3M | — | — | — |
| EPS (diluted) | $-0.70 | $-1.05 | $-1.49 | $-1.75 | $-2.37 |
| Operating cash flow | -$18.8M | -$15.7M | -$13.1M | -$12.1M | -$4.1M |
| Cash & equivalents | $0 | $0 | $0 | $0 | $0 |
| Total assets | $9.7M | $10.2M | $7.6M | $12.0M | $11.3M |
| Total liabilities | $7.3M | $6.5M | $7.1M | $3.5M | $2.1M |
| Shareholders' equity | $2.4M | $3.6M | $477,511 | $8.5M | $9.2M |
Source: SEC EDGAR filings · CIK 0001878313 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.